Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42Busulfan 41Peripheral Blood Stem Cell Transplantation 40Cyclosporine 30Tacrolimus 29Antilymphocyte Serum 28Mycophenolic Acid 26Radiotherapy 25Methotrexate 25Imatinib Mesylate 21Methylprednisolone 20Whole-Body Irradiation 19Dasatinib 17Filgrastim 16Melphalan 15Interferon-alpha 15Cord Blood Stem Cell Transplantation 15sargramostim 12nilotinib 12Cytarabine 12Etoposide 11Cyclosporins 7Alemtuzumab 7merphos 6asciminib 6Sirolimus 6Homoharringtonine 6thymoglobulin 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Chronic-Phase × lonafarnib × Clear all
NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡